Drug intelligence / Profile preview

Xifeng Zhitong

Development stage: Unknown
Lead developer: Guangxi Qiangshou Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Xifeng Zhitong is a Traditional Chinese Medicine (TCM) product developed by Guangxi Qiangshou Pharmaceutical Group, primarily indicated for the treatment of migraines and headaches associated with liver-yang hyperactivity and internal wind. Formulated as tablets or capsules, it typically contains a blend of botanical extracts such as Gastrodia elata and Uncaria rhynchophylla. The therapeutic approach focuses on extinguishing wind and calming the liver to provide analgesic effects and reduce the frequency of vascular headaches. It is widely used in China as a standard treatment for chronic migraine management.

Brand names: Xifeng Zhitong
Other names: Xifeng Zhitong PianXifeng Zhitong JiaonangXifeng Zhitong TabletXifeng Zhitong Capsule

Beyond the preview

Go deeper on Xifeng Zhitong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xifeng Zhitong.

Explore the full profile